Imatinib mesylate targets mutated KIT oncoproteins in gastrointestinal stromal tumor (GIST) and achieves a clinical response in 80% of patients. The mechanism is believed to depend predominantly on the inhibition of KIT-driven signals for tumor cell survival and proliferation. Using a mouse model of spontaneous GIST, we found that the immune system contributes substantially to the anti-tumor effects of imatinib. Imatinib therapy activated CD8+ T cells and induced regulatory T cell (T reg) apoptosis within the tumor by reducing tumor cell expression of the immunosuppressive enzyme indoleamine 2,3-dioxygenase (Ido). Concurrent immunotherapy augmented the efficacy of imatinib in mouse GIST. In freshly obtained human GIST specimens, the T cell profile correlated with imatinib sensitivity and IDO expression. Thus, T cells are critical to the anti-tumor effects of imatinib in GIST and concomitant immunotherapy may further improve outcome in human cancers treated with targeted agents.

Several metazoan splicing factors are characterized by ribonucleoprotein (RNP) consensus sequences and arginine-serine repeats (RS domain) which are essential for their function in splicing. These include members of the SR-protein family (SC35, SF2/ASF), the U1 small nuclear (sn) RNP protein (U1-70K) and the U2 snRNP auxiliary factor (U2AF). SR proteins are phosphorylated in vivo and the phosphorylation state of U1-70K's RS domain influences its splicing activity. Here we report the purification of a protein kinase that is specific for SR proteins and show that it is DNA topoisomerase I. This enzyme lacks a canonical ATP-binding motif but binds ATP with a dissociation constant of 50 nM. Camptothecin and derivatives, known to be specific inhibitors of DNA topoisomerase I, strongly inhibit the kinase activity in the presence of DNA and affect the phosphorylation state of SR proteins. Thus, DNA topoisomerase I may well be one of the SR protein kinases operating in vivo.

Oncogenic Kit mutations are found in somatic gastrointestinal (GI) stromal tumors (GISTs) and mastocytosis. A mouse model for the study of constitutive activation of Kit in oncogenesis has been produced by a knock-in strategy introducing a Kit exon 11-activating mutation into the mouse genome based on a mutation found in a case of human familial GIST syndrome. Heterozygous mutant Kit V558⌬ ͞؉ mice develop symptoms of disease and eventually die from pathology in the GI tract. Patchy hyperplasia of Kit-positive cells is evident within the myenteric plexus of the entire GI tract. Neoplastic lesions indistinguishable from human GISTs were observed in the cecum of the mutant mice with high penetrance. In addition, mast cell numbers in the dorsal skin were increased. Therefore Kit V558⌬ ͞؉ mice reproduce human familial GISTs, and they may be used as a model for the study of the role and mechanisms of Kit in neoplasia. Importantly, these results demonstrate that constitutive Kit signaling is critical and sufficient for induction of GIST and hyperplasia of interstitial cells of Cajal. Kit encodes a growth factor receptor with ligand-dependent tyrosine kinase activity (1-3). Kit ligand (KitL) is the only known ligand of the Kit receptor (4). KitL binding to the receptor mediates receptor dimerization, activation of kinase activity, and autophosphorylation. Subsequently, Kit activates several signaling cascades, leading to cell proliferation, cell survival, and other cellular responses. Kit and KitL are encoded at the White spotting (W) and Steel (Sl) loci in the mouse, respectively (4-6). Mutations at the murine W and Sl loci generate deficiencies in several major cell systems during embryogenesis and in the postnatal animal: in hematopoiesis, melanogenesis, gametogenesis, and intestinal pacemaker cells. In hematopoiesis Kit receptor signaling is critical in the stem cell hierarchy, erythropoiesis, mast cell development and function, megakaryopoiesis, and lymphopoiesis (7-10). Interstitial cells of Cajal (ICC) function as pacemaker cells in the gastrointestinal (GI) tract and they mediate inputs from the enteric nervous system to smooth muscle cells. ICC express the Kit receptor tyrosine kinase and inhibition of Kit function interferes with the autonomous movement of the GI tract (11-13).GI stromal tumor (GIST) is the most common mesenchymal neoplasm of the human intestinal tract. GISTs are a heterogeneous group of tumors, which historically had been classified either as leiomyoma, leiomyosarcoma, or GI autonomic nerve tumors (14). GISTs express Kit and they are thought to derive from a Kit ϩ or Kit low ICC progenitor or ICC through somatic mutation, based on immunophenotypic and ultrastructural similarities (15).Originally, we had identified Kit as the oncogene of an acute transforming feline retrovirus, the HZ4-FeSV (1). However, a role for Kit in human neoplasia has been emerging only more recently. First, human and murine mast cell lines were found to carry Kit-activating mutations in the activation loop of the kinas...